Weight Loss Treatment
29,90 €
Weight Loss Treatment29,90 €
Weight Loss TreatmentWeight loss injections of the GLP-1 type contain one of three active substances: semaglutide, tirzepatide or liraglutide. They differ in how often they are injected, how the dose is built up and what each product is authorised for. This page compares them by substance, explains what the doctor checks before you start or continue treatment, lists the common side effects and sets out who pays for what.
GLP-1 is one of the body's own hormones. The product information published by the European Medicines Agency describes it as a physiological regulator of appetite and calorie intake. Semaglutide and liraglutide act on the GLP-1 receptor; tirzepatide acts on the GIP receptor as well.
In practice these medicines reduce hunger and bring on the feeling of fullness sooner. They also increase the release of insulin when blood sugar is high and slow the emptying of the stomach, which is why digestive complaints are the commonest side effects at the start.
Semaglutide and tirzepatide are injected under the skin once a week, liraglutide once a day. Each product starts at a low dose that is raised in steps, so that nausea and the other digestive complaints stay more manageable; the steps for you are set by the doctor.
They are used together with a reduced-calorie diet and more physical activity, not instead of them, and they are not interchangeable: each product has its own authorised use, dose steps and injection device. All the injectable products described here are medicines subject to medical prescription (Annex II B of their EU product information).
The table compares the three substances in their weight management products, using sections 4.1 and 4.2 of the EMA product information. It is a comparison of facts, not an instruction: your dose is set by the doctor. Each substance has its own page with more detail: the semaglutide page, the tirzepatide page and the liraglutide page.
Weight-related conditions named in the product information include high blood pressure, disturbed blood fats, obstructive sleep apnoea, prediabetes and type 2 diabetes. Semaglutide and liraglutide are also the active substances of products authorised only for type 2 diabetes, and those products are not weight loss medicines; the semaglutide page explains the difference product by product.
| Substance | How it is given | Authorised for weight management in | How the dose is built up |
|---|---|---|---|
| Semaglutide | Injection under the skin once a week | Adults with a BMI of 30 or more, or of 27 to under 30 with at least one weight-related condition; adolescents from 12 years with obesity and a body weight above 60 kg | Starts at 0.25 mg and rises every 4 weeks (0.5 mg, 1 mg, 1.7 mg) to 2.4 mg after 16 weeks; in adults with a starting BMI of 30 or more, 7.2 mg is possible after at least 4 weeks on 2.4 mg |
| Tirzepatide | Injection under the skin once a week | Adults with a BMI of 30 or more, or of 27 to under 30 with at least one weight-related condition | Starts at 2.5 mg for 4 weeks, then 5 mg; further steps of 2.5 mg after at least 4 weeks on each dose; maintenance 5 mg, 10 mg or 15 mg, at most 15 mg |
| Liraglutide | Injection under the skin once a day | Adults with a BMI of 30 or more, or of 27 to under 30 with at least one weight-related condition; adolescents from 12 years and children from 6 years who meet the obesity and body weight criteria in the product information | Starts at 0.6 mg a day and rises by 0.6 mg at intervals of at least one week to 3.0 mg a day, the maintenance dose |
When you are continuing, the doctor needs to know which medicine you take, at which strength, who started it and when, and which dose step you have reached. Your weight at the start and now matters too, because the reason for continuing is read from the course of the treatment.
Your history matters: thyroid disease and a family history of medullary thyroid carcinoma, previous pancreatitis, gallstones, severe disease of the stomach or bowel, diabetic retinopathy, kidney or liver disease, pregnancy, breastfeeding and plans for pregnancy. Some of those are reasons not to start or continue at all.
Other medicines count as well, above all insulin and sulfonylureas, because the combination raises the risk of low blood sugar. Slower emptying of the stomach can also change how tablets are absorbed; the tirzepatide product information names warfarin and digoxin as examples to monitor. That is why the whole list of what you take is asked for.
A first prescription is possible only where your answers show clear indications and no contraindications. Before treatment starts, the doctor may want your current weight and height or recent results, may suggest an in-person visit to a doctor first, and may decline.
The product information also sets points at which treatment is reconsidered: for liraglutide in adults, treatment stops after 12 weeks on 3.0 mg a day if at least 5% of the starting weight has not been lost; for semaglutide in adolescents, it is re-evaluated if the BMI has not fallen by at least 5% after 12 weeks on 2.4 mg or the highest dose tolerated. For a child or adolescent, the assessment belongs with a doctor who examines them in person and can follow them up.
Unlike the injections, orlistat acts in the gut: its product information describes it as inhibiting the enzymes there that digest fat. Orlistat 120 mg capsules are subject to medical prescription in the EU (Annex II B) and are authorised, with a mildly reduced-calorie diet, for a BMI of 30 or more, or above 28 with associated risk factors. One capsule is taken with each main meal, and treatment stops after 12 weeks if at least 5% of the starting weight has not been lost. A request for orlistat 120 mg goes through the same Weight Loss Treatment service.
Orlistat 60 mg capsules have a separate EU authorisation as a medicine not subject to medical prescription, for adults with a BMI of 28 or more, for up to 6 months. In Malta, medicines that need no prescription are still supplied only by a pharmacy. Ask a pharmacist about that strength. With either strength, severe diarrhoea can make a contraceptive pill less reliable, and the product information for both recommends an additional method of contraception in that case.
Semaglutide also exists as a once-daily tablet. One tablet product is authorised only for type 2 diabetes and is not a weight loss medicine; the product information of the weight management semaglutide product also covers a tablet for adults, started at 1.5 mg a day and raised in steps of at least four weeks to 25 mg.
The commonest side effects come from the digestive system: nausea, vomiting, diarrhoea, constipation, abdominal pain, reflux, burping and bloating. They are usually strongest while the dose is being built up and ease as treatment goes on. Tiredness, dizziness and reactions at the injection site are also described, and hair loss is listed for semaglutide and tirzepatide.
Vomiting or diarrhoea that goes on can lead to dehydration, which can worsen kidney function. Drink enough and tell the doctor early rather than pushing through it.
Severe and persistent abdominal pain, particularly pain reaching through to the back with vomiting, needs urgent medical attention, because acute pancreatitis is a recognised risk; if it is suspected, the medicine is stopped. Sudden pain high on the right side of the abdomen, yellowing of the skin or eyes, or a general state that is getting worse quickly is also a reason to seek care without delay: gallstones are listed for all three substances. Swelling of the face, lips or throat and difficulty breathing can be a severe allergic reaction. In an emergency, call 112.
Two warnings appear in the special warnings of only one of the three products. Semaglutide has been linked with non-arteritic anterior ischaemic optic neuropathy (NAION), so a sudden loss of vision calls for an urgent eye examination. Liraglutide can raise the resting heart rate, so palpitations or a racing heartbeat at rest are worth reporting.
Before any procedure under general anaesthesia or deep sedation, tell the team that you use one of these medicines: cases of pulmonary aspiration have been reported, because food can stay in the stomach for longer than expected. The full list of side effects is in the leaflet in the box. Do not change the dose on your own because of a side effect: report it.
The product information for semaglutide and tirzepatide recommends contraception for women who could become pregnant during treatment. Semaglutide should be stopped at least 2 months before a planned pregnancy and tirzepatide at least 1 month before, because both stay in the body for a long time. Liraglutide should not be used in pregnancy and is stopped if you wish to become pregnant or become pregnant. The semaglutide and liraglutide products for weight management should not be used while breastfeeding.
For tirzepatide, the product information states that oral contraceptives need no change of dose. Severe vomiting or diarrhoea can still make a contraceptive pill less reliable, so tell the doctor if it happens. We do not start this treatment in pregnancy, when you are planning a pregnancy or while you are breastfeeding.
These medicines influence appetite while you use them. When treatment stops, appetite and the feeling of fullness can return to what they were before, and weight lost during treatment can come back. That is the nature of the treatment rather than a personal failure, so treatment is planned as a long-term arrangement together with changes in eating and activity, and reviewed with the doctor as it goes on.
A pause is sometimes necessary: before certain procedures, during an illness with vomiting, when pregnancy is planned or confirmed, or when side effects do not settle. A pause is a medical decision, not something to arrange alone: after several missed doses, the semaglutide product information advises considering a lower dose when treatment is restarted.
What weight loss injections cost you is made up of two separate items. The first item, 29,90 €, is what we charge, in the Weight Loss Treatment service, for the doctor to review your questionnaire. The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
Priority handling is available for 9,90 € and moves the request further up the doctor's queue, with no time promised. The second item is the medicine. You pay for it at the pharmacy, at the price that pharmacy charges, which depends on the product, the strength and the pack. Because we do not sell medicines, we do not quote their prices either; ask the pharmacy. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
Whether you are new to a GLP-1 medicine or already on one, you answer a medical questionnaire covering the medicine, your health and your other medicines, and the doctor reviews what you have written. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. If the doctor asks for records, results or a measurement, you send them through that chat.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
Medicines are not sold or posted by us. The Medicines Authority states that in Malta "all medicinal products are dispensed only from pharmacies". For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this. For medicines outside weight management there is a separate service, described on our page on private prescriptions.
We do not prescribe opioids, benzodiazepines, Z-drugs, stimulants, gabapentinoids or medical cannabis. This is our own rule and goes further than the Maltese lists of controlled drugs. It also covers appetite suppressants that act as stimulants.
We consider only medicines authorised as medicinal products. A product bought outside a pharmacy, without an authorisation and without product information, is not something the doctor can assess, and a pen offered that way may be falsified.
One doctor reviews every request in this service: Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. This review does not replace your family doctor, nor is the document entered in any Maltese state record. The doctor is not registered with the Medical Council of Malta.
In the EU, products containing semaglutide, tirzepatide and liraglutide are authorised for weight management in adults who meet the BMI criteria in their product information. Semaglutide is also the active substance of products authorised only for type 2 diabetes, which are not weight loss medicines. Which substance suits you is the doctor's decision.
Two costs are separate. The medicine is paid for at the pharmacy, at the price that pharmacy charges, so the pharmacy is the place to ask. Our fee is for the doctor's review only and never includes the medicine; the amount is given in the section on costs above.
Not with our document. POYC is open only to patients entitled to free medicines, those with a SCHV document or a pink card. Our prescription is a private route. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
Appetite and the feeling of fullness can return to what they were before, and weight lost during treatment can come back. The treatment is therefore planned as a long-term arrangement, and you decide with the doctor how long to continue and when a pause is needed.
Yes, provided the answers you give show clear indications and no contraindications; for adults, the product information requires a BMI of at least 30, or of at least 27 where a weight-related condition is present. You may be asked for your current weight or recent results; seeing a doctor in person may be recommended, and the doctor may decline. We do not start this treatment in pregnancy, when you are planning a pregnancy or while you are breastfeeding.
We can make no promise that it will be dispensed. A prescription from a doctor in another EU country can be dispensed in Malta (Article 81(3) of the Medicines Act, Cap. 458) if the pharmacist can confirm the doctor's licence. The decision rests with the pharmacist, who may refuse. You bring the printed prescription on paper together with photo identification.
Orlistat 120 mg capsules are a prescription medicine for weight loss, and a request for them goes through the Weight Loss Treatment service. Orlistat 60 mg capsules are authorised without prescription, so a pharmacist can advise you on them. Semaglutide also exists as a once-daily tablet: one tablet product is for type 2 diabetes only, and the weight management semaglutide product also covers a tablet for adults.